Evidence map›Paper›PMID 23831594›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2014

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.

Richard D Antrobus, Tamara K Berthoud, Caitlin E Mullarkey, Katja Hoschler, Lynda Coughlan, Maria Zambon, Adrian V S Hill, Sarah C Gilbert

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Viral vector-based influenza vaccines.Human vaccines & immunotherapeutics · 2016
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. CD8Nature communications · 2021
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Richard D AntrobusThe Jenner Institute, University of Oxford, Oxford, UK.
Tamara K BerthoudThe Jenner Institute, University of Oxford, Oxford, UK.
Caitlin E MullarkeyThe Jenner Institute, University of Oxford, Oxford, UK.
Katja HoschlerRespiratory Virus Unit, Public Health England, London, UK.
Lynda CoughlanThe Jenner Institute, University of Oxford, Oxford, UK.
Maria ZambonRespiratory Virus Unit, Public Health England, London, UK.
Adrian V S HillThe Jenner Institute, University of Oxford, Oxford, UK.
Sarah C GilbertThe Jenner Institute, University of Oxford, Oxford, UK.
Jenner Institute · GBPublic Health England · GBUniversity of Oxford · GB

Funding

Medical Research Council MR/J008680/1Wellcome Trust 090532
6 · The paper itself

Abstract

Current seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have previously shown that the novel candidate vaccine MVA-NP+M1 is able to boost memory T cell responses in adults aged 50-85 years. Preclinical studies have demonstrated that viral vectored vaccines can act as adjuvants when coadministered with protein-based vaccines. We have conducted a phase I clinical trial to compare the coadministration of seasonal influenza vaccine and MVA-NP+M1 with seasonal influenza vaccine alone in adults aged 50 years and above. This combination of vaccines was safe and well tolerated. T cell responses to internal influenza proteins were boosted to significantly higher levels in the group receiving MVA-NP+M1 compared with the group receiving seasonal influenza vaccine alone. Rates of seroprotection and seroconversion against the three vaccine strains were similar in both groups; however, there was a significant increase in the geometric mean titer ratio for the H3N2 component of seasonal influenza vaccine in the coadministration group. While some vaccine combinations result in immune interference, the coadministration of MVA-NP+M1 alongside seasonal influenza vaccine is shown here to increase some influenza strain-specific antibody responses and boost memory T cells capable of recognizing a range of influenza A subtypes.

Indexed as

AgedAntibodies, ViralFemaleHumansImmunity, CellularImmunity, HumoralInfluenza A virusInfluenza, HumanInfluenza VaccinesMaleMiddle AgedT-LymphocytesVaccines, DNAViral Core ProteinsViral Matrix ProteinsViral VaccinesAntibodies, ViralInfluenza VaccinesM1 protein, Influenza A virusMVA vaccineVaccines, DNAViral Core ProteinsViral Matrix ProteinsViral Vaccines

Identifiers

PMID23831594
PMCPMC3978791
OpenAlexW2072546058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.